#TrialUpdate
LightNews LightNews
vjoncology.bsky.social
Terence Friedlander, MD, shares 3.5-year #EV103 Cohort K data at #ESMO25 — enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC.

🎥 Watch: buff.ly/kWn5KkI

#UroOnc #UroSoMe #Blcsm #ImmunoOnc #CTSM #TrialUpdate
EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC - VJOncology
Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103...
buff.ly
November 11, 2025 at 3:54 PM
vjoncology.bsky.social
At #ESMO25, Dr Llombart Cussac presents #EMPRESS trial results: giredestrant led to greater Ki67 reduction and stronger ER/PR decreases vs tamoxifen in premenopausal ER+/HER2- early #BreastCancer.

🎥 Watch: buff.ly/vLWxnoe

#BCSM #CTSM #TrialUpdate #Oncology
EMPRESS: giredestrant vs tamoxifen in ER+/HER2- early breast cancer - VJOncology
Antonio Llombart Cussac, MD, PhD, Arnau de Vilanova Hospital of Valencia, Valencia, Spain, discusses results from the Phase II EMPRESS...
buff.ly
November 10, 2025 at 3:54 PM
vjoncology.bsky.social
🎥Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, @HKUniversity, shares highlights from the #MetastaticBreastCancer track at #ESMO25 - including updates from VIKTORIA-1, novel ADCs in #TNBC, and PRO/QoL insights.

Watch here ➡️ buff.ly/E4FLjXD

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #ESMO25
Metastatic breast cancer updates at ESMO 2025 - VJOncology
Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, provides an overview of the metastatic breast...
buff.ly
November 9, 2025 at 9:01 AM
vjoncology.bsky.social
Emmanuel Seront, MD, PhD, discusses the Phase II RENALUT trial of 177Lu-PSMA-617 in metastatic ccRCC post-TKI/IO therapy, exploring PSMA-targeted radioligand therapy as a new option for resistant disease

🎥 buff.ly/dLhijGf

#KidneyCancer #KCSM #CTSM #TrialUpdate #RadioligandTherapy #RadOnc #ESMO25
RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC - VJOncology
Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...
buff.ly
November 8, 2025 at 9:05 AM
vjoncology.bsky.social
Charles Geyer, MD, reports #DESTINYBreast05 results in HER2+ early BC.

💊 T-DXd > T-DM1 for iDFS & DFS
🧠 Reduced brain mets risk
⚖️ Manageable safety → potential new SoC

🎥 buff.ly/r3AwOkw

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #Immunotherapy #HER2 #ESMO25 @myesmo.bsky.social
DESTINY-Breast05: T-DXd vs T-DM1 in high-risk HER2+ early breast cancer - VJOncology
Charles Geyer, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, discusses results from the Phase III DESTINY-Breast05 trial (NCT04622319), comparing...
buff.ly
November 7, 2025 at 9:01 AM
vjhemonc.bsky.social
Recently, Gottfried von Keudell shared the long-term follow-up results from the Phase II ELM-2 study evaluating the efficacy of the bispecific antibody odronextamab in patients with R/R #FollicularLymphoma.

Watch here:

👉 buff.ly/6GUNfkY 👈

#ImmunoOnc #LYMsm #CTSM #TrialUpdate #SOHO2025 #MedSky
November 6, 2025 at 5:42 PM
vjoncology.bsky.social
Alexandra Drakaki, MD, PhD, discusses FORAGER-1 testing LY3866288 in FGFR3-altered tumors

🧬 200 mg BID = well tolerated
💥 Encouraging antitumor activity in mUC
🧪 Activity seen post-FGFR inhibitor exposure

🎥 buff.ly/ozWqgdG

#BladderCancer #Blcsm #UroOnc #UroSoMe #CTSM #TrialUpdate #ESMO25
FORAGER-1: dose optimization of LY3866288 in FGFR3-altered tumors - VJOncology
Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, discusses the Phase I FORAGER-1 study (NCT05614739) of LY3866288, a...
buff.ly
November 2, 2025 at 9:01 AM
vjoncology.bsky.social
Shigehira Saji, MD, PhD, shares final OS data from EMERALD in 1L HER2+ #BreastCancer.

💊 Eribulin or taxane + trastuzumab + pertuzumab
📈 Median OS >6 years, similar across arms
🧬 PIK3CA = poor prognosis, no impact on treatment effect
🎥 buff.ly/R9sZAVk

#BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25
EMERALD: eribulin plus dual HER2 blockade in first-line HER2+ breast cancer - VJOncology
Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, comments on discusses final survival results from the EMERALD study (NCT03264547)...
buff.ly
November 1, 2025 at 9:01 AM
vjhemonc.bsky.social
In a recent interview, Jesús San Miguel comments on the updated findings of the Phase III GEM2017FIT trial, which evaluated the efficacy of DaraKRd versus KRd in patients with newly diagnosed #MultipleMyeloma.

Click to watch:

👉 buff.ly/RVZjPoG 👈

#CTSM #TrialUpdate #IMS25 #MMsm #Myeloma #BloodSky
October 30, 2025 at 5:42 PM
vjoncology.bsky.social
Clara Steiner, MD, presents new transcriptomic findings from COSMIC-313 in #RCC at #ESMO25

🧬 RNA sequencing of baseline tumors
🔍 Distinct gene signatures by metastasis site
🌡️ Pathways: metabolism, hypoxia, EMT

🎥 Watch: buff.ly/dIMvnoC

@myesmo.bsky.social #KCSM #CTSM #TrialUpdate #UroOnc #UroSoMe
COSMIC-313: transcriptomic predictors of metastatic sites in RCC - VJOncology
Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, discusses a post-hoc transcriptomic analysis from...
ow.ly
October 28, 2025 at 7:30 PM
vjoncology.bsky.social
At #ESMO25, Shigehira Saji shares new MonarchE data on Ki-67 as a biomarker in HR+/HER2– high-risk #BreastCancer:

📊 High Ki-67 = ↑ recurrence risk
💊 Abemaciclib + ET effective across all Ki-67 subgroups
✅ Broad benefit, regardless of Ki-67 change

🎥 Watch: buff.ly/F1mziDY

#BCSM #CTSM #TrialUpdate
MonarchE: Ki-67 dynamics and prognostic value in HR+/HER2- breast cancer - VJOncology
Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, discusses the MonarchE trial (NCT03155997) evaluating the prognostic and predictive value...
ow.ly
October 24, 2025 at 8:02 AM
vjhemonc.bsky.social
We recently spoke with Karthik Ramasamy, who shared insight into the DREAMM-9 trial, aimed at optimizing the dose of belantamab mafodotin for the treatment of transplant-ineligible newly diagnosed #MultipleMyeloma.

Watch here: 👉 buff.ly/szIDc29

#Myeloma #MMSM #HemOnc #CTSM #TrialUpdate #MedSky
October 22, 2025 at 3:04 PM
vjhemonc.bsky.social
Want to hear findings from the EPCORE NHL-2 trial evaluating epcoritamab plus intensive chemo for patients with R/R #DLBCL eligible for autoSCT?

Watch our interview with Marek Trněný of @charlesuni.cuni.cz from #SOHO2025:

👉 buff.ly/GHh6dYG 👈

#LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
October 20, 2025 at 5:28 PM
vjhemonc.bsky.social
At #iwCLL2025, Barbara Eichhorst discussed the efficacy of epcoritamab monotherapy in first-line Richter’s transformation, highlighting 2-year follow-up results from the EPCORE CLL-1 trial.

Watch the interview here:

👉 buff.ly/UvDvXD3 👈

#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
October 18, 2025 at 3:02 PM
vjhemonc.bsky.social
Watch our interview from #IMS25 with Larry Anderson to hear about the updated safety and efficacy data from the randomized Phase III AURIGA study.🩸

Click here:

🎥 buff.ly/TclKlrd

#CTSM #TrialUpdate #MMsm #Myeloma #HemOnc #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social
October 14, 2025 at 9:01 AM
vjhemonc.bsky.social
🎥 Marta Coscia shares findings from the BRUIN CLL-321 trial investigating pirtobrutinib versus idelalisib plus rituximab or bendamustine + rituximab in patients with CLL/SLL previously exposed to a covalent BTKi:

👉 buff.ly/rBWUBYh 👈

#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky
October 13, 2025 at 8:29 AM
vjoncology.bsky.social
⭐ Jason Mouabbi, MD, of @mdanderson.bsky.social, shares an overview of key studies in breast cancer presented at #ASCO25:

🎥 buff.ly/0IeuM2Z

@ascocancer.bsky.social #BCSM #BreastCancer #CTSM #TrialUpdate #ImmunoOnc
ASCO 2025 highlights in breast cancer: ASCENT-04, SERENA-6, and more - VJOncology
Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of key studies in...
buff.ly
October 6, 2025 at 2:54 PM
vjoncology.bsky.social
⭐ Fabrice André, MD, PhD, shares KEYNOTE-756 results:

➡️ Adding pembrolizumab to neoadjuvant chemo improved pCR in high-risk ER+/HER2- breast cancer. EFS data pending...

🎥 buff.ly/0R25Yjb

#ESMOBreast25 #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc
KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer - VJOncology
Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, discusses the Phase III KEYNOTE-756 study (NCT03725059) of pembrolizumab with neoadjuvant chemotherapy...
buff.ly
October 4, 2025 at 2:54 PM
vjhemonc.bsky.social
Thank you to the lovely Hang Quach of @unimelb.bsky.social for speaking with us at #IMS25 to share results from part one of the Phase I/II DREAMM-20 trial investigating belantamab in pts with R/R #MultipleMyeloma.🩸

Watch now:

🎥 buff.ly/zBD1MpN

#MMsm #Myeloma #CTSM #TrialUpdate #ImmunoOnc #HemOnc
October 3, 2025 at 5:02 PM
vjhemonc.bsky.social
🎥 Jennifer Marvin-Peek of @mdanderson.bsky.social shares the results of a Phase I/II study evaluating an all-oral triplet regimen combining decitabine, venetoclax, & ivosidenib or enasidenib in IDH1-/IDH2-mutated AML:

👉 buff.ly/Z3WVJCU 👈

#SOHO2025 #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc
October 1, 2025 at 5:00 PM
vjoncology.bsky.social
⭐ Yue Che, MD, shares RAISN trial: ICG-guided sentinel node biopsy is feasible & well tolerated in stage I testicular cancer, aiming to reduce chemo use:

🎥 buff.ly/kF09jHH

#EAU25 #UroOnc #UroSoMe #CTSM #TrialUpdate #TSCsm
RAISN: indocyanine green-guided lymph node dissection in testicular cancer - VJOncology
Yue Che, MD, University Hospital of Duesseldorf, Düsseldorf, Germany, discusses the evolving role of retroperitoneal lymph node dissection and therapy...
buff.ly
October 1, 2025 at 2:54 PM
vjoncology.bsky.social
⭐ Michael Gnant, MD, FACS, reviews long-term endocrine therapy in HR+ breast cancer: benefit for high-risk pts, ovarian suppression in ASTRRA, & elinzanetant for vasomotor symptoms:

🎥 buff.ly/hfp5orD

@ascocancer.bsky.social #ASCO25 #BreastCancer #BCSM #CTSM #TrialUpdate
Tailoring endocrine therapy: risk-based strategies and symptom management in HR+ breast cancer - VJOncology
Michael Gnant, MD, FACS, Medical University of Vienna, reviews four key studies on long-term endocrine therapy in premenopausal HR+ breast...
buff.ly
September 30, 2025 at 2:54 PM
vjhemonc.bsky.social
At #IMS25, we caught up with Xavier Leleu of to hear about the Phase III IRAKLIA trial investigating isatuximab administered subcutaneously via an on-body injector versus intravenously in patients with R/R #MultipleMyeloma:

🎥 buff.ly/T67u8VR

#MMsm #Myeloma #TrialUpdate @myeloma-society.bsky.social
September 30, 2025 at 9:01 AM
vjoncology.bsky.social
🎥 Domenica Lorusso, MD, PhD, reports relacorilant + nab-paclitaxel improved PFS & OS in platinum-resistant ovarian cancer w/ consistent safety:

➡️https://buff.ly/M7ojYej

#ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate
ROSELLA trial: relacorilant plus nab-paclitaxel in ovarian cancer - VJOncology
Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, discusses secondary endpoint findings from the Phase...
buff.ly
September 29, 2025 at 2:54 PM
vjoncology.bsky.social
🎥 Peter Albers, MD, comments on PROBASE: men with negative biopsy unlikely to develop prostate cancer within 5 yrs. Doubling PSA values key to refining high-risk group & avoiding overdiagnosis.

➡️ buff.ly/4gKsdFN

#EAU25 #UroOnc #UroSoMe #PCSM #CTSM #TrialUpdate
Updates in the PROBASE study of risk adapted screening for prostate cancer - VJOncology
Peter Albers, German Cancer Research Center (DKFZ), Heidelberg & Heinrich-Heine-University, Düsseldorf, Germany, comments on the PROBASE trial of risk adapted...
buff.ly
September 28, 2025 at 2:54 PM